Articles related to SMALL CELL LUNG CANCER (SCLC)
Serplulimab First Anti-PD-1 to Improve Overall Survival in Extensive-Stage SCLC
The addition of the PD-1 inhibitor serplulimab to chemotherapy significantly prolonged survival compared with chemotherapy alone as first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). Interim analysis of the phase 3 ASTRUM-005 study – comparing serplumimab plus chemotherapy to chemotherapy alone in 1st line extensive stage SCLC – showed a median OS of 15.4 months with serplulimab compared with 10.9 months with placebo. Patients who received serplulimab also had significantly longer median progression-free survival (PFS) 5.8 vs. 4.3 months respectively. The study included 585 patients with untreated extensive stage-SCLC, were randomized 2:1 to serplulimab (4.5 mg/kg) or placebo every 3 weeks. All patients received carboplatin and etoposide every 3 weeks for up to four cycles.
Oncology, Medical June 27th 2022
Smoker’s Painless Skin Nodules Flag a Fatal Diagnosis
An 87-year-old white man presented to a hospital emergency surgical department with two round, grayish-brown nodules on his abdomen. He had no other complaints except feeling tired and dizzy for the last few months. He had a 120 pack-year smoking history but was not taking any medications and had not experienced a cough, chest pain, shortness of breath, or other breathing problems.
Cardiology April 27th 2022
Adebrelimab Improves PFS, OS in Extensive-Stage Small Cell Lung Cancer
Compared to chemotherapy alone, adebrelimab plus chemotherapy nearly doubled 2-year OS and more than tripled 1-year PFS in patients with extensive-stage SCLC, according to results presented earlier this month at the AACR Annual Meeting 2022. The phase 3 CAPSTONE-1 study evaluated adebrelimab in combination with carboplatin plus etoposide, as first-line treatment for ES-SCLC.
Oncology, Medical April 26th 2022
Immunotherapy Combo Fails to Boost Survival in Limited-Disease SCLC
A randomized phase II trial has found that consolidation therapy with nivolumab (Opdivo) plus ipilimumab (Yervoy) after chemoradiotherapy did not lead to better survival outcomes for patients with small cell lung cancer (SCLC). The study enrolled 222 patients with stage I-IIIB histologically or cytologically confirmed limited-disease SCLC, and adequate hematologic, renal, lung, and pulmonary function. The combination regimen yielded no improvement in overall survival, and grade 3 adverse events were approximately 2.5 times more common in the dual therapy group.
Internal Medicine November 30th 2021
Negative Trials Close the Book on Once-Promising SCLC Drug
A once-hopeful antibody-drug conjugate for small-cell lung cancer (SCLC) failed to demonstrate a survival benefit in two large, randomized studies, and was found to be mostly toxic. The negative trial results have led to the end of a drug that was considered a promising potential antidote to deadly SCLC.
Internal Medicine October 29th 2021
First-Line Pembrolizumab Combo Improves PFS in Patients w. Extensive-Stage SCLC
The Journal of Clinical Oncology published the double-blind, phase 3 KEYNOTE-604 clinical trial study results, which sought to compare pembrolizumab plus etoposide and platinum (EP) with placebo plus EP in treatment-naïve patients with ES-SCLC.
Internal Medicine June 29th 2020